Clinical trials: Nutritional Evaluation
Pompe Disease, Glycogen Storage Disease Type II
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
The purpose of this study is to see how molecules called pharmacological chaperones affect the cells of patients with Pompe disease.
- Trial name
- NCT00515398
- Testing
- Observation
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Amicus Therapeutics
Hypertension, Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Trial name
- VALENCIA (NCT01368536)
- Testing
- Valturna, Amlodipine, Chlorthalidone
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 975 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on: weight loss and waist circumference, blood pressure, cholesterol, glucose other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α…
- Trial name
- NCT00134199
- Testing
- CP-945,598, sibutramine
- Where
- 15 sites in United States
- Volunteers
- 282 people
- Sponsor
- Pfizer
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage.
- Trial name
- NCT07097987
- Testing
- WM formula Group, Control group
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Hyperlipidemia
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05260411
- Testing
- AK102
- Where
- 2 sites in China
- Volunteers
- 246 people
- Sponsor
- Akeso
MPS II, Hunter Syndrome (MPS II)
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system.
- Trial name
- NCT07236606
- Testing
- RGX-121-3102
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- REGENXBIO Inc.
Prediabetes, Hyperglycemia
Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects
In this trial, the investigational product , the active ingredients which has been proven to reduce postprandial glucose in healthy and diabetic patients, will be tested.
- Trial name
- NCT02541344
- Testing
- Dose 1 of IQP-VV-102, Dose 2 of IQP-VV-102
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01494987
- Testing
- Ranolazine, Glimepiride, Diet
- Where
- 140 sites in United States, Czechia and 10 more
- Volunteers
- 431 people
- Sponsor
- Gilead Sciences
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Atenas association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- ATENAS (NCT05144360)
- Testing
- Atenas
- Sponsor
- EMS
Over Weight, Obesity
Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers
The study will assess the safety and performance of an intragastric auto-inflating and degradable balloon
- Trial name
- NCT01753609
- Testing
- Tulip capsule
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tulip Medical Ltd.
Diabetes Mellitus, Type 2
GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.
The purpose of this study is to collect information on how Xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes. Participants will get Xultophy® as prescribed by the study doctor.
- Trial name
- GOAL (NCT04838743)
- Testing
- IDegLira
- Where
- 42 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Novo Nordisk A/S
Healthy Participants Study, Overweight and Obese Adults
A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults.
- Conditions
- Healthy Participants Study, Overweight and Obese Adults, First in Man Study to Evaluate Initial Safety
- Trial name
- NCT07721597
- Testing
- ZP6590, solution for injection
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Non-alcoholic Steatohepatitis, Hypertriglyceridemia
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects…
- Conditions
- Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
- Trial name
- NCT02681055
- Testing
- MN-001
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.
- Trial name
- NCT06548815
- Testing
- GZR4
- Where
- China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Diabetes Mellitus, Type 1
Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature
A prospective, multicenter evaluation of performance and safety of the Eversense Gemini System with flash glucose measurement feature.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT07386340
- Testing
- Continuous Glucose Monitoring System
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Senseonics, Inc.
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes.
- Trial name
- NCT07228117
- Testing
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 389 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor
The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements (YSI glucose…
- Trial name
- PRECISE (NCT02154126)
- Testing
- Continuous Glucose Monitoring Device (Senseonics)
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Senseonics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.